Management of Patients with Chronic Myeloid Leukemia

As recently as the 1990s the approach to chronic myeloid leukemia (CML) treatment was to allograft those who were eligible and palliate those who were not. Palliation with alpha interferon (IFNα) could prolong survival substantially for the 15–30 % of patients who had IFNα-responsive disease but quality of life for these patients was often markedly impaired.